Breaking News
admin
Apr 15 2025
6CTI Clinical Trial & Consulting (CTI) has transformed from a small Ohio-based startup into a major force in global clinical research. With a legacy of over 25 years in advancing patient care and medical innovation, the company continues to deepen its local roots while expanding its global reach. In a conversation with Tyler Allchin, Managing Director at JobsOhio, CTI’s Founder, Chairman, and CEO Tim Schroder shared insights into the company's growth and future.
Built on Expertise and Purpose:
Founded in 1999 with a focus on transplantation research, CTI has grown into one of the world’s most prominent mid-sized clinical research organizations (CROs), now operating across five continents. According to Schroder, this growth has been fueled by the company’s commitment to expanding its service offerings, embracing new clinical trial designs, and most importantly, investing in its people.
CTI boasts one of the highest employee retention rates in the industry. This stability has allowed the company to retain deep scientific and operational expertise, strengthen long-term relationships, and consistently deliver high-quality work to clients.
Growing with Cincinnati’s Life Sciences Sector:
Cincinnati’s emergence as a hub for life sciences has been instrumental to CTI’s success. The region’s rich mix of innovation, world-class academic institutions, and strong economic development initiatives has attracted top-tier talent and cutting-edge research opportunities. CTI has strategically tapped into these resources to fuel its expansion and enhance its impact.
Partnerships have been central to this success. CTI collaborates closely with JobsOhio, the University of Cincinnati, Cincinnati Children’s Hospital, and other healthcare institutions to foster a vibrant ecosystem. These collaborations, along with CTI’s therapeutic expertise, have positioned the company—and the region—as a leader in life sciences innovation.
Advancing Cell and Gene Therapy:
A major area of focus for CTI is cell and gene therapy (CGT), where the company has built a strong track record over the past 15 years. CTI has supported the development of many pioneering CGT treatments and has played a role in more than half of all FDA and EMA approvals in this space.
Ohio is uniquely suited to lead in CGT development, with its advanced research hospitals, state-of-the-art manufacturing capabilities, and comprehensive preclinical and clinical infrastructure. CTI’s well-established partnerships and regulatory knowledge give it an edge in helping clients accelerate breakthrough therapies.
One recent milestone in the field is the FDA’s approval of a CAR-T therapy for solid tumors—a major advancement that holds promise for patients with previously untreatable cancers. Schroder sees this as a sign of the exciting directions CGT is heading, especially in expanding treatment to autoimmune diseases and solid tumors.
Embracing Innovation Amid Uncertainty:
Despite ongoing fluctuations in the biotech market throughout 2025, CTI is moving forward with confidence and adaptability. The company is embracing emerging technologies such as AI-powered trial optimization and remote patient monitoring through wearable devices. These innovations are reshaping the way clinical trials are conducted—making them more efficient, cost-effective, and patient-friendly.
Looking ahead, CTI is committed to guiding its clients through an ever-changing landscape, ensuring that promising therapies continue their path toward approval and commercialization. By staying focused on collaboration—with sponsors, patients, and healthcare organizations—CTI aims to remain at the forefront of clinical research innovation.
With a strong foundation in Ohio and a growing global impact, CTI continues to shape the future of medicine—one breakthrough at a time.
Source: https://www.fiercebiotech.com/sponsored/how-cti-shaping-clinical-research-ohio-and-beyond
This is non-financial/medical advice and made using AI so could be wrong
